SGLT2 in CKD with DM.

DAPA CKD trial assessing the benefit of SGLT2 inhibitor Dapagliflozin in adults with Chronic Kidney Disease with or without Diabetes will be stopped early due to overwhelming benefit for reduction in worsening of Renal function or Renal death in Dapagliflozin arm compared to placebo,March2020

1 Like

LikeAnswersShare
Diabetic nephropathy Yes certainly it is vary good combination as DAPA reduces albuminurea Increases GFR and yes lowers bsl by secretion of glucose In pts without diabetes it is not a first choice as cuse is urinary infection which is contradictory to its use
Thank you doctor
0

Cases that would interest you